Treatment practices in heart failure with preserved left ventricular ejection fraction: A prospective observational study

Peltier, Marcel; Houpe, D.; Cohen‐Solal, Alain; Béguin, M.; Lévy, F.; Tribouilloy, Christophe

doi:10.1016/j.ijcard.2006.07.033

Cited by 6 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About 2/3 patients with heart dysfunctions were treated until improvement. The therapy usually included diuretics, cardiac glycoside drugs or angiotensin-converting enzyme inhibitor drugs [29]. Most of the patients mentioned above continued to use Herceptin weekly, and no more clinical heart problems were observed as a result.…”

Section: Discussionmentioning

confidence: 99%

Adverse reaction of a combined treatment for unresectable liver cancer

Ren¹,

Jiang

Peng³

2014

Open Medicine

View full text Add to dashboard Cite

AbstractTo investigate the adverse reactions of transcatheter arterial chemoembolization (TACE) combined with trastuzumab in the treatment of unresectable live cancer, 85 unresectable liver cancer patients were treated with 35 mg epirubicin, with lipiodol and gelatin sponge granule as the embolic agent, and trastuzumab (4mg/kg) was administered intravenously. All the adverse reactions were investigated by blood routine examination and the checking of liver, renal and thyroid functions on the postoperative 2nd and 30th day. No patients died of direct medication. The main adverse reactions included haematological toxicity, liver function lesion and postoperative syndromes such as nausea, vomiting, fever and liver area aching. Two days after the treatment, the amount of the serum total bilirubin (TB) and white blood cell (WBC) increased dramatically, while platelet (PLT) changed a little, and creatinine (Cr) and blood urea nitrogen (BUN) did not change at all. Thirty days after the treatment, blood routine, liver and renal functions were examined, demonstrating that the liver function remained unchanged, PLT decreased apparently, WBC was lower, and Cr and BUN changed slightly compared to those before the treatment. The combined treatment is safe for unresectable liver cancer and thus can be used as a routine intervention method.

show abstract

Section: Discussionmentioning

confidence: 99%

Adverse reaction of a combined treatment for unresectable liver cancer

Ren¹,

Jiang

Peng³

2014

Open Medicine

View full text Add to dashboard Cite

show abstract

“…It is known that ACEI poses effects mainly on the restoration of vascular property: resistance and compliance [14], so this study focuses on the change in R and C before and after ACEI treatment. By applying the fast parameters estimation algorithm, a unique solution of RC corresponding to HF patients' blood pressure can be attained.…”

Section: Methodsmentioning

confidence: 99%

Fast Parameters Estimation in Medication Efficacy Assessment Model for Heart Failure Treatment

Ren

Pan

et al. 2012

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Introduction. Heart failure (HF) is a common and potentially fatal condition. Cardiovascular research has focused on medical therapy for HF. Theoretical modelling could enable simulation and evaluation of the effectiveness of medications. Furthermore, the models could also help predict patients' cardiac response to the treatment which will be valuable for clinical decision-making. Methods. This study presents a fast parameters estimation algorithm for constructing a cardiovascular model for medicine evaluation. The outcome of HF treatment is assessed by hemodynamic parameters and a comprehensive index furnished by the model. Angiotensin-converting enzyme inhibitors (ACEIs) were used as a model drug in this study. Results. Our simulation results showed different treatment responses to enalapril and lisinopril, which are both ACEI drugs. A dose-effect was also observed in the model simulation. Conclusions. Our results agreed well with the findings from clinical trials and previous literature, suggesting the validity of the model.

show abstract

“…The prevalence of DHF ranged from 34-55% with hypertension, CAD, or diabetes mellitus being present in the majority of DHF subjects in the studies reviewed [8,10,[12][13][14]. Data analysis by Peltier et al [14] of 263 subjects from the Epidémiologie et Traitement de l'Insuffisance Cardiaque dans la Somme study sample demonstrated that hypertension and CAD were more common etiologies for DHF among those≥75 years of age when compared with younger study subjects. Another small study found 51% of subjects had a history of prior myocardial infarction [8].…”

Section: Introductionmentioning

confidence: 99%

Myocardial Ischemia in Patients with Diastolic Dysfunction and Heart Failure

et al. 2010

View full text Add to dashboard Cite

Coronary artery disease is present in 40-55% of patients with diastolic heart failure, and myocardial ischemia is both a cause and a precipitant of diastolic heart failure. Failure to recognize and treat acute and chronic ischemia in patients with this disorder results in rapid disease progression and poor outcomes. In diastolic heart failure patients without obstructive coronary artery disease, ischemia can be induced by other diseases that diminish perfusion gradient, cause myocardium to outgrow blood supply, or decrease diastolic filling time. In this article, we review the role of ischemia and development of fibrosis in the epidemiology, pathophysiology, and evaluation of patients with diastolic dysfunction and diastolic heart failure.

show abstract

Treatment practices in heart failure with preserved left ventricular ejection fraction: A prospective observational study

Cited by 6 publications

References 29 publications

Adverse reaction of a combined treatment for unresectable liver cancer

Adverse reaction of a combined treatment for unresectable liver cancer

Fast Parameters Estimation in Medication Efficacy Assessment Model for Heart Failure Treatment

Myocardial Ischemia in Patients with Diastolic Dysfunction and Heart Failure

Contact Info

Product

Resources

About